View More Recent Stories
-
TD Cowen Reiterates Buy Rating on Incyte (INCY)
-
Incyte (INCY) PT Raised to $68 at BofA Securities
-
Goldman Sachs Reiterates Neutral Rating on Incyte (INCY)
-
TD Cowen Reiterates Buy Rating on Incyte (INCY)
-
JMP Securities Reiterates Market Perform Rating on Incyte (INCY)
-
Incyte (INCY) Announces Positive Topline Results from Pivotal Study of Tafasitamab in R/R Follicular Lymphoma
-
Syndax Pharmaceuticals (SNDX) PT Raised to $34 at Citi
-
BMO Capital Reiterates Underperform Rating on Incyte (INCY)
-
Incyte (INCY) PT Raised to $67 at RBC Capital
-
FDA Approves Incyte's (INCY) Niktimvo for cGVHD
-
Incyte (INCY) PT Raised to $66 at RBC Capital
-
Incyte (INCY) Misses Q2 EPS by 269c; raises guidance
-
Incyte (INCY) PT Lowered to $81 at Oppenheimer
-
BMO Capital Downgrades Incyte (INCY) to Underperform
-
Incyte (INCY) Announces Final Results of Tender Offer
-
Incyte (INCY) Announces Preliminary Results of Tender Offer
-
Increasing unusual option volume: SANA FFIE INCY MBLY CRDO OPRA EFA DM IMVT
-
4 Buy-rated Healthcare stocks with 30-45% upside
